Surrozen Strengthens Board of Directors with the Appointment of Eric Bjerkholt
05 Abril 2023 - 7:30AM
Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a
company pioneering targeted therapeutics that selectively activate
the Wnt pathway for tissue repair and regeneration, today announced
that Eric Bjerkholt has been appointed to the Board of Directors.
Surrozen’s Board of Directors now includes nine members with
extensive experience across diverse disciplines in biotechnology
and pharmaceutical development.
Mr. Bjerkholt brings extensive business leadership experience
across a broad range of roles and is currently CFO of Chinook
Therapeutics. He most recently served as CFO of Aimmune
Therapeutics, Inc. overseeing the financial reporting, budgeting,
internal controls, investor relations, business development,
facilities and information technology functions and led the
acquisition of Aimmune by Nestle Health Science for $2.6 billion.
He also spent 13 years at Sunesis Pharmaceuticals, Inc., where in
addition to CFO, he served in various capacities, including
Executive Vice President of Corporate Development and Finance,
Corporate Secretary and Chief Compliance Officer. Previously, Mr.
Bjerkholt held senior executive finance roles at IntraBiotics
Pharmaceuticals, Inc, LifeSpring Nutrition, Inc. and Age Wave, LLC
and spent seven years in healthcare investment banking at J.P.
Morgan & Company, Inc. He is currently a member of the board of
directors and chair of the Audit Committee of CalciMedica, Inc. and
member of the board of directors of Cerus Corporation. Mr.
Bjerkholt holds an MBA from Harvard Business School and a
Cand.oecon. from the University of Oslo in Norway.
“We are fortunate to have someone with Eric’s diverse experience
and record of accomplishments join the Surrozen Board,” said Craig
Parker, Chief Executive Officer of Surrozen. “I’m confident
Surrozen will benefit from Eric’s insights, strategic acumen and
broad biotechnology industry experience.”
“This is an exciting time to join the Surrozen Board,” said Mr.
Bjerkholt. “I look forward to working with the team as they focus
on developing breakthrough technologies to selectively activate the
Wnt pathway in disease areas where there is significant unmet
medical need.”
About Surrozen
Surrozen is a clinical stage biotechnology company discovering
and developing drug candidates to selectively modulate the Wnt
pathway. Surrozen is developing tissue-specific antibodies designed
to engage the body’s existing biological repair mechanisms with a
current focus on inflammatory bowel, severe liver and eye diseases.
Please visit www.surrozen.com for more information.
Forward Looking Statements
This press release contains certain forward-looking statements
within the meaning of the federal securities laws. Forward-looking
statements generally are accompanied by words such as “will,”
“plan,” “intend,” “potential,” “expect,” “could,” or the negative
of these words and similar expressions that predict or indicate
future events or trends or that are not statements of historical
matters. These forward-looking statements include, but are not
limited to, statements regarding Surrozen’s discovery, research and
development activities, in particular its development plans for its
product candidates SZN-1326, SZN-043, and SZN-413, including
anticipated clinical development timelines and the availability of
data, and the potential for such product candidates to be used to
treat human disease. These statements are based on various
assumptions, whether or not identified in this press release, and
on the current expectations of the management of Surrozen and are
not predictions of actual performance. These forward-looking
statements are provided for illustrative purposes only and are not
intended to serve as, and must not be relied on as, a guarantee, an
assurance, a prediction, or a definitive statement of fact or
probability. Actual events and circumstances are difficult or
impossible to predict and will differ from assumptions. Many actual
events and circumstances are beyond the control of Surrozen. These
forward-looking statements are subject to a number of risks and
uncertainties, including the initiation, cost, timing, progress and
results of research and development activities, preclinical or and
clinical trials with respect to SZN-1326, SZN-043, SZN-413 and
potential future drug candidates, the Company’s ability to fund our
clinical trials and development efforts, whether with existing
funds or through additional fundraising; Surrozen’s ability to
identify, develop and commercialize drug candidates; Surrozen’s
ability to successfully complete preclinical and clinical studies
for SZN-1326, SZN-043, SZN-413, or other future product candidates;
the effects that arise from volatility in global economic,
political, regulatory and market conditions, which may be adversely
affected by the conflict between Russia and Ukraine; the ongoing
coronavirus (COVID-19) pandemic; and all other factors discussed in
Surrozen’s Annual Report on Form 10-K for the year ended December
31, 2022 under the heading “Risk Factors,” and other documents
Surrozen has filed, or will file, with the Securities and Exchange
Commission. If any of these risks materialize or our assumptions
prove incorrect, actual results could differ materially from the
results implied by these forward-looking statements. There may be
additional risks that Surrozen presently does not know, or that
Surrozen currently believes are immaterial, that could also cause
actual results to differ from those contained in the
forward-looking statements. In addition, forward-looking statements
reflect Surrozen’s expectations, plans, or forecasts of future
events and views as of the date of this press release. Surrozen
anticipates that subsequent events and developments will cause its
assessments to change. However, while Surrozen may elect to update
these forward-looking statements at some point in the future,
Surrozen specifically disclaims any obligation to do so, except as
required by law. These forward-looking statements should not be
relied upon as representing Surrozen’s assessments of any date
after the date of this press release. Accordingly, undue reliance
should not be placed upon the forward-looking statements.
Investor Contact:Investorinfo@surrozen.com
Surrozen (NASDAQ:SRZN)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Surrozen (NASDAQ:SRZN)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024